Publications


20202019201820172016201520142013

Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI—Evidence from in vitro and in vivo models

Eugeni Entchev , Ingrid Jantzen, Philippe Masson, Stephanie Bocart, Bruno Bournique, Jean-Michel Luccarini, Andre Bouchot,Olivier Lacombe, Jean-Louis Junien, Pierre Broqua, Mireille Tallandier

PLOS ONE, May 2020

AASLD 2020: Efficacy of the panPPAR agonist lanifibranor on the histological endpoints NASH resolution and fibrosis regression is similar in type‐2 diabetic and non‐diabetic patients: additional results of the NATIVE Phase 2b trial in non‐cirrhotic NASH

Télécharger

AASLD 2020: Effect of the panPPAR agonist lanifibranor on plasma biomarkers of liver necro‐inflammation and fibrosis in non‐cirrhotic NASH patients: additional results of the NA11 12TIVE Phase 2b trial.13

Télécharger

AASLD 2020 : Selection based on SAF Activity score instead of NASH CRN NAFLD Activity Score leads to selection of a more severe NASH with more advanced fibrosis patient cohort in the NATIVE phase 2b study of the panPPAR agonist Lanifibranor

Télécharger

Discovery of YAP-TEAD Protein-Protein interaction inhibitors for treating Malignant Pleural Mesothelioma

Discovery of YAP-TEAD Protein-Protein interaction inhibitors for treating Malignant Pleural Mesothelioma
AACR San Diego, Sep. 2019
A Soude, M. Barth, JM Luccarini, S. Delaporte, F. Chirade, G. Cheret, A. Boulay, C.Valaire, M. Dorchie, C. Estivalet, P. Tuya-Boustugue, C. Montalbetti, R. Tranchant*, D. Jean*, L. Quetel*, JB. Assié,*
I. Konstantinova, JL. Junien & P. Broqua

Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate

the Journal of Medicinal Chemistry, June 2018
Benaïssa Boubia, Olivia Poupardin, Martine Barth, Jean Binet, Philippe Peralba, Laurent Mounier, Elise Jacquier, Emilie Gauthier, Valérie Lepais, Maryline Chatar, Stéphanie Ferry, Anne Thourigny, Fabrice Guillier, Jonathan Llacer, Jérome Amaudrut, Pierre Dodey, Olivier Lacombe, Philippe Masson, Christian Montalbetti, Guillaume Wettstein, Jean-Michel Luccarini, Christiane Legendre, Jean-Louis Junien, and Pierre Broqua

Intracellular GAG Level in Leukocytes is a Promising Pharmacodynamic Biomarker for MPS VI

MPS Symposium, Aug 2018
Paul Harmatz, Laura Pollard, Nick Cantley, JoAnn Johnson, Olivier Lacombe, Jean-Louis Junien, Jean-Louis Abitbol, Mireille Tallandier

In vivo assessment of lung fibrosis’ prevention using the pan-PPAR agonist lanifibranor in the TbetaRIIgammak-fib (Transgenic Mouse Model of Scleroderma) mouse model of systemic sclerosis

ACR, Oct 2018
Emma C. Derrett-Smith, Shiwen Xu, David Abraham, Olivier Lacombe,Pierre Broqua, Jean-Louis Junien, Irena Konstantinova and Christopher P. Denton

Evidence for Altered Peroxisome Proliferator Activated Receptor (PPAR) Pathway Activity in a Transgenic Mouse Model of Scleroderma (TbetaRIIgammak-fib): Analysis of Mouse Skin, Lung and Explanted Cells

ACR, Oct 2018
Emma Derrett-Smith, Rachel Hoyles, Xu Shi-Wen, Olivier Lacombe, Pierre Broqua, Jean-Louis Junien, Irena Konstantinova, Christopher P Denton

Discovery of promising anti-cancer drug combination using YAP-TEAD inhibitors with standard of care treatment in mesothelioma and NSCLC cells

EORTC, Nov 2018
Anne Soude, Martine Barth, Séverine Delaporte, Florence Chirade, Geneviève Cheret, Sylvie Contal, Aude Boulay, Christelle Valaire, Christian Montalbetti, Irena Konstantinova, Jean-Louis Junien & Pierre Broqua.

IVA337, a PAN-PPAR agonist, reduces NASH features and inhibits the inflammasome in murin models of NASH

EASL, The International Liver Congress, Amsterdam, September 19-23
Guillaume Wettstein, Laurence Poekes, Fiona Oakley, Patrick Faye, Jean-Michel Luccarini, Pierre Broqua, Jean-Louis Junien, Derek Mann, Isabelle Leclercq, Irena Konstantinova

The New-Generation Pan-Peroxisome Proliferator-Activated Receptor Agonist IVA337 Protects the Liver From Metabolic Disorders and Fibrosis

Hepatology Communications, June 2017
Guillaume Wettstein, Jean-Michel Luccarini, Laurence Poekes, Patrick Faye, Francine Kupkowski, Vanessa Adarbes, Evelyne Defrêne, Céline Estivalet, Xavier Gawronski, Ingrid Jantzen, Alain Philippot, Julien Tessier, Pascale Tuyaa-Boustugue, Fiona Oakley, Dereck A. Mann, Isabelle Leclercq, Sven Francque, Irena Konstantinova, Pierre Broqua, and Jean-Louis Junien

The pan-PPAR agonist IVA337 has anti-fibrotic effects in multiple in vitro and in vivo fibrosis models

4th Systemic Sclerosis World Congress, Lisbon, February 18-20
Irena Konstantinova, Jean-Michel Luccarini, Evelyne Defrêne, Céline Estivalet, Ingrid Jantzen, Julien Tessier.

A rational approach for the discovery of inhibitors of NSD2 for the treatment of cancer

AACR 2016, New Orleans, April 16-20
Claudia Fromond, Xavier Espanel, Séverine Estevez, Vanessa Adarbes, Stéphanie Bocart, Bruno Loillier

IVA336 a Potential Substrate Reduction Therapy for Mucopolysaccharidose type-VI, -I, and -II Diseases

MPS 2016, Bonn, July 13-14
Mireille Tallandier ,Philippe Masson, Eugeni Entchev, Sebastien Jacquet, Ingrid Jantzen, Olivier Lacombe, Véronique Douet

A rational approach for the discovery of NSD2 inhibitors for the treatment of multiple myeloma

2nd Annual Epigenetics Discovery Congress, London, September 8-9
Xavier Espanel, Séverine Estevez, Vanessa Adarbes, Stéphanie Bocart, Bruno Loillier, Séverine Delaporte, Elina Mandry

A rational approach for the discovery of inhibitors of NSD2 for the treatment of cancer

Epigenetics and Cancer , Keystone Colorado , January 25-30.
Xavier Espanel, Séverine Estevez, Vanessa Adarbes, Stéphanie Bocart, Bruno Loillier, Séverine Delaporte, Elina Mandry, Anne Soudé, Laurent Chene, Philippe Masson, Benaïssa Boubia, Christian Montalbetti, Pierre Broqua and Claudia Fromond.

Ultrafast LC-UV-ELSD-MS confirming the high quality of Inventiva’s screening collection

SLAS 2015, Washington DC, February 7-11.
Frédéric Bell, Clément Gaiffe, Amandine Vessot Jérôme Amaudrut, Sylvaine Marie, Philippe Masson.

Identification of G9a inhibitors by Alphalisa™ and hit confirmation using MT-Glo™

SLAS 2015, Washington DC, February 7-11.
Philippe Masson, Vanessa Adarbes, Stéphanie Bocart , Séverine Estevez , Bruno Loillier, Laurent Chêne, Christian Montalbetti, Claudia Fromond, Benaissa Boubia and Xavier Espanel.

A rational approach for discovery of inhibitors of YAP-TEAD interaction

AACR, Philadelphia, April 18-22
Claudia Fromond, Laurent Chene, Anne Soude, Martine Barth, Christian Montalbetti and Pierre Broqua

A rational approach for the discovery of inhibitors of NSD2 for the treatment of cancer

AACR, Philadelphia, April 18-22
Claudia Fromond, Xavier Espanel, Anne Soudé, Laurent Chene, Philippe Masson, BenaïssaBoubia, Christian Montalbetti and Pierre Broqua

Identification of G9a inhibitors by AlphaLisa™ technology and hit confirmation using MT-Glo™

AACR, Philadelphia, April 18-22
Claudia Fromond, Xavier Espanel, Laurent Chene, Philippe Masson, BenaïssaBoubia, Christian Montalbetti, Pierre Broqua

A rational approach for the discovery of inhibitors of the YAP-TEAD interaction

Drug Discovery Chemistry , San Diego , April 21-23
Christian Montalbetti, Claudia Fromond, Laurent Chene, Anne Soude, Martine Barth, Sylvie Contal and Pierre Broqua

Rodent Pharmacokinetics and in vitro ADME Properties of IV3086: An orally available and brain penetrant NURR1/RXR Activator

ISSX – 13th European Meeting, Glasgow, June 22-25
Bruno Bournique, Didier Bressac, Emmanuel Hardillier, Olivier Lacombe

Inhibition of two NADPH-independent enzymatic activities: Aldehyde oxidase and Xanthine oxidase inhibition

18th International Conference on Drug-Drug Interactions ,Washington, June 29- July 1st
Didier Bressac, Rachel Dechaume, Aurélie Péraire, Emmanuel Hardillier, Christelle Gondran, Eric Lecocq, Olivier Lacombe

A Rational Approach for the Discovery of NSD2 Inhibitors for the Treatment of Cancer

Miptec 2015, Basel, Sept 19-23
13th annual Discovery On Target, Boston, MA, September 22-23
Xavier Espanel, Séverine Estevez, Vanessa Adarbes, Stéphanie Bocart, Bruno Loillier, and Christian Montalbetti

Discovery of YAP-TEAD Protein-Protein interaction (PPI) inhibitors for the treatment of cancer

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Boston, MA, November 5-9
Anne Soude, Martine Barth, Stéphanie Bocart, Frédéric Thoreau, Elina Mandry, Sylvie Contal

Identification of novel EZH2 inhibitor scaffolds

26th EORTC-NCI-AACR symposium, Barcelona, Nov 18-21.
Xavier Espanel, Laurent Chene, Anne Soude, Séverine Estevez, Vanessa Adarbes, Bruno Loillier, Benaissa Boubia, Philippe Masson, Christian Montalbetti, Pierre Broqua & Claudia Z. A. Fromond.

A rational approach for discovery of inhibitors of YAP-TEAD interaction

26th EORTC-NCI-AACR symposium, Barcelona, Nov 18-21.
Laurent Chene, Anne Soude, Christelle Valaire, Severine Delaporte, Sebastien Jacquet, Yves Cambet, Isabelle Braccini, Martine Barth, Christian Montalbetti, Pierre Broqua & Claudia Z-A Fromond.

A Selective NURR1/RXR activation for treating Parkinson’s disease

Keystone Nuclear Receptors ,Taos , January 10-15.
B.Boubia, O. Lacombe, M. Tallandier

Identification of novel EZH2 inhibitor scaffolds

Keystone Cancer Epigenetics, Santa Fé, February 4-9.
Xavier Espanel, Christian Montalbetti, Claudia Fromond

Development and automation of a fibrotic phenotypic screening using a High Content Screening approach

Keystone Fibrosis, Keystone Colorado, March 23-28.
Laurent Chêne, Anne Soude, Philippe Masson and Xavier Espanel

Screening Library Enrichment: Criteria that matter, timely manner

Openeye European User Meeting, Mery sur Oise, May 14-16.
Jérôme Amaudrut, Fabrice Guillier

In Vitro-In Vivo Correlation (IVIVC) for clearance estimation in earlyADME : the importance of unbound fraction assessment in plasma and microsomes

20th International Symposium on Microsomes and Drug Oxidations, Leinfelden, May 18-22.
Didier Bressac, Rachel Dechaume, Jeanne-Marie Bony, Olivier Lacombe

Solubility toolbox for successful design of drug candidates

10th International Symposium on Drug Analysis, Liège, June 23-25.
Frédéric Bell, Caroline Durand, Nathalie Urban

Compound-oriented preparative HPLC purification platform

10th International Symposium on Drug Analysis, Liège, June 23-25.
Nathalie Urban, Frédéric Bell, Cyrielle Couchoux

Discovery and optimization of indoline derivatives as new LXR agonists

248TH ACS National Meeting & Exposition, San Francisco, August 10-14.
Dominique Potin, Jérôme Amaudrut

A Rapid LC-hrMS Method for Metabolite Identification Simultaneously to Metabolic Stability Assessment on Microsomes at an Early Screening Stage

International Mass Spectrometry,Geneve,August 24-29.
Emmanuel Hardillier, Didier Bressac, Olivier Lacombe

A Useful Relationship between In Vivo Rat Kp Brain and In Vitro Caco-2 Cells Efflux Ratio

19th North American Congress of the International Society for the Study of Xenobiotics, San Francisco, Oct 19-23.
B. Bournique, JM. Bony, D.Bressac, B. Cautain, R.Dechaume, V. Douet, C. Eymann, C. Gondran, E.Hardillier, L. Nicolas, O. Lacombe.

Interaction scanning libraries: A general strategy for scaffold functionalization

International Symposium on Advances in Synthetic and Medicinal Chemistry, Moscow, May 5-8.
Fabrice Guillier, Jérôme Amaudrut, Jonathan Llacer, Jérôme Gonzalez

Supporting the Reactivity Assessment of an IVA Acyl-Glucuronide Derivative

HPLC 2013, Amsterdam, June 16-20.
Emmanuel Hardillier, Béatrice Cautain, Olivier Lacombe

Synthesis of substituted phenyl acetic acid and 5-membered heterocycles derivatives

18th European Symposium on Organic Chemistry , Marseille, July 7-12.
L. Mounier, M. Barth, B. Boubia

Practical synthesis of N-substituted naphthyridine

18th European Symposium on Organic Chemistry, Marseille, July 7-12.
Laurent Mignon

Contact investisseurs


Inventiva
50 rue de Dijon
21121 Daix, France
Email: finance@inventivapharma.com
Tel: +33 (0)3 80 44 75 00

Patti Bank
Managing Director
ICR Westwicke
Patti.Bank@westwicke.com
D 415-513-1284
San Francisco, CA
www.westwicke.com